Global Business Travel Group, Inc. (GBTG): what the price requires
At today's price, Global Business Travel Group, Inc. (GBTG) is priced for today's economics sustained for ~8.6 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/GBTG
Headline
| Field | Value |
|---|---|
| Ticker | GBTG |
| Company | Global Business Travel Group, Inc. |
| Current price | $9.40/sh |
| Composition | Travel revenue 79% / Products and professional services revenue 21% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 2.1% |
| Operating margin today | 3.8% |
| Margin compression implied | -1.7pp |
| Must persist for | 8.6y |
| Multiple paid | 58x operating income |
The operating-margin requirement is derived from the framework's value band at year 6, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 8.2% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.2 years.
Reconcile: at the x-ray's 9.3% required return this reads ~11 years; the models below use their own rates.
How unusual the bet is: high
| Reference | Value |
|---|---|
| cohort percentile (of 210 peers) | 96 |
| sustained it ~8.6 years at this level | 17% |
| implied end-window share | 0% |
Valuation X-Ray
Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 5.87x | 4 | expensive |
| Earnings | 3.63x | 2 | expensive |
| Relative | 1.57x | 5 | expensive |
| Growth | 0.87x | 3 | justifies |
Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.2%); the inversion above states its own rate.
Per-Model Detail (n=14)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $0.62 | 15.17x | yes | FCF base $0.0B, growth 21% (input: historical growth), terminal g 4.0%, WACC 7.2%, 7yr projection |
| DCF Exit Multiple | Growth | $11.22 | 0.84x | yes | Exit EV/EBITDA: 19.1x / 21.1x / 23.1x (bear / base = today's held flat / bull), 7yr |
| Relative Valuation | Relative | $6.31 | 1.49x | yes | P/E 30.28x (blended: static sector reference 20x + trailing (TTM) 54x), scenarios: 24.5x / 30.3x / 36.0x (bear / base = reference held flat / bull), EV/EBITDA 15.42x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $1.87 | 5.03x | yes | BV/sh $3.10, ROE (TTM) 5.6%, ke 9.3% |
| Two-Stage Excess Return | Asset | $1.40 | 6.72x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $10.80 | 0.87x | yes | Rev $2.9B, growth 21% (input: historical growth; tapered), Terminal P/S: 1.3x / 1.7x / 2.0x (bear / base = today's held flat / bull, cap 12x) |
| Peter Lynch Fair Value | Relative | $1.92 | 4.90x | yes | EPS $0.16, growth 1% (input: historical EPS growth), PEG=46.59 (Overvalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | — | — | no | — |
| Residual Income | Asset | $1.34 | 7.02x | yes | BV $3.10 + 5yr PV of (ROE (TTM) 5.6% − Kₑ 9.3%) × BV; BV grows 3.6%/yr |
| Graham Number | Asset | $3.34 | 2.82x | yes | √(22.5 × EPS $0.16 × BVPS $3.10) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $4.90 | 1.92x | yes | EBITDA $0.29B × sector EV/EBITDA 13.0x |
| FCF Yield | Earnings | $0.01 | 940.50x | yes | FCF $26.0M / Kₑ 9.3% — zero-growth perpetuity (excluded from median) |
| SBC-Adj FCF Yield | Earnings | — | — | no | — |
| Ben Graham Formula | Earnings | $5.16 | 1.82x | yes | EPS $0.16 × (8.5 + 2×15.0%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | $0.04 | 235.12x | yes | BV $3.10 × (ROIC 0.1% / WACC 7.2%) (excluded from median) |
| P/Sales Sector | Relative | $8.48 | 1.11x | yes | Revenue $2.94B × sector P/S 1.5x |
| PEG Fair Value | Relative | $6.00 | 1.57x | yes | EPS $0.16 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x |
| Earnings Yield | Earnings | $1.73 | 5.44x | yes | EPS $0.16 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $1.1b |
| Net debt / NOPAT (after-tax) | 13.25x |
| Net debt / operating income (pre-tax) | 10.47x |
| Interest coverage | 1.1x |
| Share count CAGR (dilution) | 4.3% |
| Burning cash | no |
Bullet Takeaways
- Management is buying back stock aggressively (authorization raised to $600 million) at a depressed price near $9, a capital-allocation signal that it sees value while integrating the CWT acquisition.
- The price is a durability premium: only the growth-DCF reaches $9, while asset and earnings-power frames land near $1.40 to $1.87 on thin returns (ROE 5.6%, ROIC 0.1%), so the bet is that post-CWT scale converts low margins into real earnings.
- The risks are disintermediation of the travel-management model and a levered balance sheet: net debt near $1.1 billion against only $78 million of trailing operating income, with interest coverage under 1x.
Bull Case
Start with what management is doing with the cash, because it tells you how the team sees the value. The board lifted the share-repurchase authorization to $600 million, a $300 million increase, a clear statement that with the stock near $9 they would rather buy their own equity than chase other uses. For a company emerging from the recovery in corporate travel and integrating a large acquisition, choosing buybacks at this price is the kind of capital-allocation signal that aligns management with shareholders. Free cash flow is being directed at repurchases and debt rather than empire-building.
The business those buybacks are shrinking is a scaled, recurring travel-management platform. Amex GBT generates revenue in two primary ways the 10-K lays out directly, travel revenues and products-and-professional-services revenues (FY2025 10-K, accession 0001628280-26-015817), with the travel side roughly four-fifths of the mix. Managed corporate travel is a sticky, contracted business: large enterprises outsource their travel programs on multi-year deals, and switching providers is disruptive, which gives the platform durable volume and data advantages. The CWT acquisition adds scale and is expected to deliver $155 million of cost synergies, with $55 million targeted in 2026, layered on top of AI-driven cost optimization.
The operating leverage is starting to show. Q4 2025 swung to net income of $111 million from a $134 million loss a year earlier, and full-year 2026 guidance calls for revenue growth of 19% to 21% to $3.235 billion to $3.295 billion and adjusted EBITDA of $615 million to $645 million, up 16% to 21%. A platform with high incremental margins, a large fixed-cost base now being leveraged across a bigger CWT-enlarged volume, and management buying back stock at a depressed price is the setup the bull case rests on: thin reported margins today that scale as synergies and volume compound.
Bear Case
The advantage Amex GBT has leaned on, being the trusted intermediary that books and manages corporate travel, is exactly the kind of moat that technology can erode. The whole value proposition is aggregating supply, negotiating rates, and servicing complex itineraries, but airlines and hotels increasingly push direct booking, new distribution standards let suppliers bypass intermediaries, and AI agents are becoming capable of planning and booking travel without a traditional travel-management company in the middle. Each of those trends chips at the take rate on the travel revenues that make up roughly 80% of the business. The 10-K's own framing of its metrics as tools to evaluate the performance of the business (FY2025 10-K, accession 0001628280-26-015817) underlines that the model depends on transaction volume and the spread on it, both of which disintermediation pressures.
The demand side is structurally uncertain too. Corporate travel never fully returned to its pre-pandemic trajectory, and the permanent shift to video meetings removed a slice of routine business trips that may not come back. That leaves Amex GBT competing for share of a market whose long-run size is smaller than it once looked, against rivals and against the option of simply not traveling. In a recession, corporate travel budgets are among the first cuts, and the company's thin operating margin near 2.7% means a modest volume decline swings results sharply.
The balance sheet turns that operating sensitivity into real risk. Net debt sits near $1.1 billion against trailing operating income of only about $78 million, and interest coverage is under 1x, a precarious combination if the CWT integration slips or travel demand softens. The valuation reflects how much has to go right: asset, earnings-power, and peer-multiple models all land far below the price, with the excess-return frames near $1.40 to $1.87 on a thin returns base, and only the growth-DCF reaches $9. The price is a bet that the platform out-runs disintermediation and that CWT synergies arrive on a levered balance sheet, with little cushion if the moat keeps eroding.
Valuation
Inverting the $9.36 price (June 27, 2026) puts the embedded bet on long persistence of premium economics, around 8.5 years of duration on the model's lever, against a thin current operating margin near 2.7% and an implied margin near 2%. The engine characterizes the price as elevated: asset, earnings-power, and peer-multiple models all say richly valued, and only the growth-DCF reaches it, a moat-and-durability premium for a business whose reported returns are currently low.
The model X-ray is lopsided because trailing profitability is thin. The excess-return and residual-income models land near $1.34 to $1.87 off a $3.10 book value with a 5.6% trailing ROE, the ROIC-justified frame near $0.04 on a 0.1% ROIC, and earnings-power value is not even applicable because normalized EBIT is non-positive. Against those, the exit-multiple DCF lands near $11, the discounted-future-market-cap method near $11 on roughly 21% revenue growth, the relative-valuation method near $6 on a blended P/E inflated by a 54x trailing multiple, and the P/S-sector method near $8.50. The blended landing across applicable methods is near $2.
The spread is the information. Every frame anchored to current earnings or book value says expensive, because Amex GBT does not yet earn much on its asset base; only the frames that capitalize the projected post-CWT growth reach the price. The peer set, RBA, CSGP, SGI, EZPW, and UTI, is a loose marketplace-and-services comparison rather than a clean travel-management cohort. The investable question is whether the 19% to 21% guided revenue growth and CWT synergies convert the thin margin into real earnings power before disintermediation and a levered balance sheet bite. At $9 the price is a normalization wager with limited cushion: net debt near $1.1 billion against $78 million of operating income and sub-1x interest coverage is the reason the downside is real if the ramp slips.
Catalysts
Amex GBT reported Q4 2025 results that beat expectations, swinging to net income of $111 million from a $134 million loss a year earlier, with EPS of about $0.16 versus a street estimate near $0.02. The company issued full-year 2026 guidance for revenue growth of 19% to 21% to $3.235 billion to $3.295 billion and adjusted EBITDA of $615 million to $645 million, up 16% to 21%, and the board increased the share-repurchase authorization to $600 million.
The defining catalyst is the CWT acquisition and its integration. Management expects $155 million of total cost synergies, with $55 million targeted in 2026, layered on AI-driven cost optimization, so the pace of synergy capture is the key swing factor on margins and the most direct lever on the equity value at this price. The data points to watch are total transaction volume and the take rate on travel revenues, since those reveal whether the platform is holding share against direct booking and AI-driven disintermediation. Corporate travel demand and the broader macro backdrop are the variables that decide whether the guided high-teens revenue growth holds, and continued buybacks are the steady support for per-share results.
Sources: Amex GBT Q4 2025 results and 2026 guidance (investors.amexglobalbusinesstravel.com, StockTitan, TipRanks, 2026); FY2025 10-K (accession 0001628280-26-015817).
Peer Cohorts (Per Segment, With Filing Citations)
Global Business Travel (consolidated) (reported)
- EXPE (EXPEDIA GROUP, INC.)
- (no filing in the citation store)
- BKNG (Booking Holdings Inc.)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.